Search

Discover how microbiome research is revealing the role that bacteria play in cancer treatment.

For men with inherited mutations in BRCA1 and BRCA2, a new program at MSK provides a “one-stop shop” for highly personalized cancer screening and surveillance.

Researchers discover that a subset of lung adenocarcinomas are aggressive because of mutations that allow them to block ferroptosis, a type of cell death.

In our recently published review paper we provide a comprehensive update on the cardiotoxicities associated with contemporary breast cancer treatment and the latest strategies for their prevention, detection, and management.

When considering adjuvant therapy preferences for younger patients ages 50 to 69 with early-stage, low genomic risk breast cancer, is it reasonable to omit radiotherapy or endocrine therapy after lumpectomy? A large retrospective cohort study at MSK found that locoregional recurrence rates were significantly lower for those who completed at least one form of adjuvant therapy after lumpectomy.

Wider negative margins do not improve local control for ductal carcinoma in situ or invasive carcinoma when they are treated with lumpectomy and radiation therapy, our recent literature review shows.

Memorial Sloan Kettering Cancer Center, along with five other elite academic institutions, will share an unprecedented total of $540 million in new financial support from Ludwig Cancer Research.

MSK experts discuss risk factors, symptoms, and treatment for male breast cancer.